

DAFTAR PUSTAKA

1. American Cancer Society. *Cancer Facts & Figures 2022*. Atlanta: American Cancer Society; 2022.
2. Alteri R. *Breast Cancer Facts & Figures 2015-2016*. American Cancer Society: Inc. Atlanta; 2016.
3. International Agency for Research on Cancer. *GLOBOCAN 2020: Cancer incidence and mortality worldwide*. Lyon: World Health Organization; 2020.
4. Kementerian Kesehatan Republik Indonesia. *Kanker Payudara Paling Banyak di Indonesia, Kemenkes Targetkan Pemerataan Layanan Kesehatan*. Jakarta: Kemenkes RI; 2022.
5. Ardiansyah AO. *Tips Mengatasi Efek Samping Kemoterapi*. Airlangga University Press; 2021.
6. Peoples AR. Nausea And Disturbed Sleep As Predictors Of Cancer-Related Fatigue In Breast Cancer Patients: A Multicenter NCORP Study. *Supportive Care In Cancer*; 2016.
7. Pidada EM. Kajian Penggunaan Antiemetika Pada Pasien Kanker Payudara Dengan Terapi Sitostatika Di Bangsal Rawat Inap Kelas III RSUD Dr. Moewardi Surakarta Periode Januari-Desember 2016. *Jurnal Kesehatan*. 2018;2(8):2-3.
8. Safitri A, Septiyana R, Damayanti F, Masruriati E, Suwarni S. Studi Pemberian Terapi Suportif Antiemetika pada Pasien Kanker Payudara di RSUD Dr. Adhyatma, MPH Provinsi Jawa Tengah Periode 2023. *Indones J Health Res Innov*. 2024;1(3):185-9.
9. Fauzi DAS, Hajrah, Sastyarina Y. Evaluasi Penggunaan Obat Antiemetik pada Penderita Kanker Payudara Pasca Kemoterapi. *Proc Mul Pharm Conf*. 2021;14(1):222-7.
10. Kementerian Kesehatan Republik Indonesia. *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara*. Jakarta: Kemenkes RI; 2018. p.1-111.
11. Kumar V. *Robbins and cotran pathologic basis of disease* 9th ed. Philadelphia: Sauders Elsevier; 2016.
12. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol*. 2010;17(6):1471-1474.
13. Makki J. Diversity of breast carcinoma: Histological ubtypes and clinical relevance. *Clinical medicine insights pathology*; 2015. p. 23-31.
14. Sjamsuhidajat R. *Buku Ajar Ilmu Bedah* Edisi 3. Jakarta: EGC; 2014.

15. Suyatno. *Bedah Onkologi Diagnosis dan Terapi*. Jakarta: CV. Sagung Seto; 2014.
16. Nurarif AH, Kusuma H. *Asuhan Keperawatan Praktis Berdasarkan Penerapan Diagnosa NANDA, NIC, dan NOC*. Yogyakarta: Mediacion; 2016.
17. Brown LD. Cellular mechanisms of chemotherapy. In: *Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook*. 2015.
18. Utaminingrum W, Hakim L, Raharjo B. Evaluasi kepatuhan dan respon mual muntah penggunaan antiemetik pada pasien kanker payudara yang menjalani kemoterapi. *Pharmacy*. 2013;10(2):159–170.
19. National Comprehensive Cancer Network. *NCCN Guidelines for Patients: Nausea and Vomiting*. Version 1.2016. Plymouth Meeting, PA: NCCN; 2016.
20. Wilbur MB, Birrer MJ, Spriggs DR. Chemotherapy-induced nausea and vomiting. *N Engl J Med*. 2016;177–179.
21. Firmansyah AM. *Penatalaksanaan Mual dan Muntah yang Diinduksi Kemoterapi*. Jakarta: Cermin Dunia Kedokteran; 2010.
22. Susanti L. *Karakteristik Mual dan Muntah serta Upaya Penanggulangan oleh Penderita Kanker yang Menjalani Kemoterapi*. Medan: Universitas Sumatera Utara; 2011.
23. Hesketh PJ. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2017;35(28):3240–3261.
24. Jeffery H, Richard D, James-Chatgilaou G. *Clinical Pharmacy: A Practical Approach*. Australia: Society of Hospital Pharmacists of Australia; 1996. p.360.
25. Widagdo PA. Pengaruh aromaterapi lemon dan relaksasi otot progresif terhadap penurunan intensitas mual muntah setelah kemoterapi. *J Ilmu Keperawatan dan Kebidanan*. 2014;2(1):24–33.
26. American Cancer Society. *Chemotherapy Drugs: How They Work*. Atlanta: American Cancer Society; 2015.
27. Multinational Association of Supportive Care in Cancer; European Society for Medical Oncology. *Antiemetic Guidelines*. 2023.
28. Badan Pengawas Obat dan Makanan Republik Indonesia. *Informatorium Obat Nasional Indonesia*. Jakarta: Sagung Seto; 2009.
29. Kentjono WA, Herawati S, Mengko SK, Wahyuni SS. Update management of head and neck cancer. *Workshop of Nasopharyngeal Cancer Chemotherapy*. Surabaya; 2015.
30. Hilarius DL, Kloeg PH, Wall EVD, Heuvel JJG, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice. *Support Care Cancer*. 2012;20:107–117.

31. Dall GV, Britt KL. Estrogen effects on the mammary gland in early and late life and breast cancer risk. *Front Oncol.* 2017;7:110.
32. Lee K, Kruper L, Dieli-Conwright CM, Mortimer JE. The impact of obesity on breast cancer diagnosis and treatment. *Curr Oncol Rep.* 2019;21:41.
33. Perwitasari DA. Kajian penggunaan antiemetika pada pasien kanker dengan terapi sitostatika di rumah sakit di Yogyakarta. *Maj Farm Indones.* 2006;17(2):91–97.
34. Ariyani AF, Purnamayanti A, Kirtishanti A. Efektivitas ondansetron sebagai profilaksis mual dan muntah pada pasien kanker payudara stadium III pasca kemoterapi. *J Islamic Pharm.* 2022;7(1):41–45.
35. Nindya SR, Bakti S. Terapi mual muntah pasca kemoterapi. *J THT-KL.* 2016;9(2):74–83.
36. Septasari FS, Susilowati S. Analisis drug related problems pada pasien kanker payudara di RSUD KRMT Wongsonegoro Semarang tahun 2022. *J Ilmu Farmasi dan Farmasi Klinik.* 2024;2(1):26–41.
37. Fatma EPL, Choiriyah M, Hidayah R. Effectiveness of acupressure on decreasing nausea-vomiting due to chemotherapy and pain in breast cancer patients. *JKM.* 2018;3(2):75–84.
38. Amelia W. Evidence based nursing self-management untuk mengurangi konstipasi pada pasien kanker payudara yang menjalani kemoterapi. *J Keperawatan Muhammadiyah.* 2017;2(2):119–125.
39. Wijayanti N, Rahmawati F, Pramugyono. Adverse drug reaction of docetaxel chemotherapy in breast cancer at Bhayangkara Hospital Kediri. *JMPF.* 2023;13(3):153–165.
40. Vij S, Dhasmana DC, Bala S, Verma SK. Efficacy of antiemetic regimens for prevention and treatment of chemotherapy-induced nausea and vomiting. *Indian J Med Paediatr Oncol.* 2020;41(6):819–824.
41. Suzuki K, Yokokawa T, Kawaguchi T, et al. Triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine in breast cancer. *Sci Rep.* 2024;14:28271.
42. Check DK, Reeder-Hayes KE, Zullig LL, et al. Racial variation in antiemetic use and health care utilization. *Support Care Cancer.* 2016;24(12):4839–4847.
43. Ohzawa H, Miki A, Hozumi Y, et al. Comparison between palonosetron and granisetron. *Oncol Lett.* 2015;9(1):119–124.
44. Clemons M, Dranitsaris G, Sienkiewicz M, et al. Individualized versus standard antiemetic therapy. *Breast.* 2020;54:278–285.
45. Oliva D, Andersson BA, Shamoun L, et al. SNP-directed antiemetic treatment. *Anticancer Res.* 2023;43(6):2671–2681.

46. Yip CCH, Li L, Lau TKH, et al. Evaluation of contemporary antiemetic regimens. *Hong Kong Med J*. 2023;29(1):49–56.
47. Sakai H, Tsurutani J, Ozaki Y, et al. Olanzapine-based prophylactic antiemetic therapy (ERICA study). *Ann Oncol*. 2025;36(1):31–42.
48. Yeo W, Ngai NTY, Yip CCH, et al. Risk factors associated with chemotherapy-induced nausea and vomiting. *Cancer Manag Res*. 2024;16:283–297.
49. Deb S, Hopefl R. Simulation of drug–drug interactions between chemotherapeutic and antiemetic drugs. *DARU J Pharm Sci*. 2023;31(1):95–105.
50. US Department of Health and Human Services. *Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0*. Washington DC; 2017.
51. Almasdy D, Eptiyeni E, Khamri D, Kurniasih N. The use of complementary and alternative medicine among breast cancer patients. *J Young Pharm*. 2018;10(2):145–147.
52. Mehnert A, Koch U. Psychological comorbidity and quality of life in breast cancer patients. *Psychooncology*. 2018;17(5):477–485.
53. Zhang H, Zhang L, Li Y, et al. Breast cancer laterality and molecular subtype. *Breast Cancer Res Treat*. 2018;170(3):623–632.
54. Arisanti JP, Saptarina N, Andarini YD. Evaluasi penggunaan obat kemoterapi pada penderita kanker payudara. *Pharmasipha*. 2020;4(2):1–8.
55. Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of trastuzumab-based chemotherapy. *Ann Oncol*. 2010;21(11):2153–2160.
56. Arianto RP, Agustina R, Fadraersada J. Analisis regimen kemoterapi kanker payudara. *Proc Mulawarman Pharm Conf*. 2017;6(1):58–65.
57. World Health Organization. *Breast Cancer*. Geneva: World Health Organization; 2020.
58. Navari RM. Risk factors for chemotherapy-induced nausea and vomiting. *Support Care Cancer*. 2018;26(4):1187–1194.
59. Septasari FS, Susilowati S. Analisis drug related problems pada pasien kanker payudara. *J Ilmu Farmasi dan Farmasi Klinik*. 2024;2(1):26–41.
60. Hesketh PJ. Chemotherapy-induced nausea and vomiting. *N Engl J Med*. 2008;358(23):2482–2494.
61. Escobar Y, Cajaraville G, Virizuella JA, et al. Incidence of chemotherapy-induced nausea and vomiting. *Support Care Cancer*. 2015;23(10):2833–2840.
62. Katzung BG, Trevor AJ. *Basic and Clinical Pharmacology*. 15th ed. New York: McGraw-Hill Education; 2021.